Scientific Publications

Scientific publications are developed in collaboration with key experts.

This page is intended as an educational resource for healthcare professionals. The list of Acadia-sponsored publications below may contain information about doses, uses, formulations and populations different from product labelling or contain information about investigational compounds or uses not approved by the FDA. Please refer to the product’s Full Prescribing Information.

Filter by:

Showing 12 of 79 Results

January 15, 2023 Preclinical

Pimavanserin reverses multiple measures of anxiety in a rodent model of post-traumatic stress disorder

European Journal of Pharmacology

January 10, 2023 Parkinson's Disease Psychosis

Health care resource utilization patterns among patients with Parkinson’s disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics

Journal of Medical Economics

December 14, 2022 Parkinson's Disease Psychosis

Mortality risk in patients with Parkinson’s disease-related psychosis treated with pimavanserin compared with other atypical antipsychotics: a cohort study

Drug Safety

November 20, 2022 Schizophrenia

Pimavanserin exposure–response analyses in patients with schizophrenia. Results from the phase 2 ADVANCE study

Journal of Clinical Psychiatry

October 27, 2022 Major Depressive Disorder

Adjunctive pimavanserin in patients with major depressive disorder: combined results from two randomized, double-blind, placebo-controlled, phase 3 studies

Psychopharmacology Bulletin

October 6, 2022 Dementia-related Psychosis

Clinical outcomes and treatment patterns of older adults with dementia-related psychosis by dementia type in the United States

BMC Geriatrics

October 5, 2022 Parkinson's Disease Psychosis

Motor- and cognition-related safety of pimavanserin in patients with Parkinson’s disease psychosis

Frontiers in Neurology

October 1, 2022 Parkinson's Disease Psychosis

Role of pimavanserin treatment-continuity on discharge from long-term care: assessing the quality of antipsychotic medication review

Senior Care Pharmacist

September 6, 2022 Schizophrenia

Effects of adjunctive pimavanserin and current antipsychotic treatment on QT interval prolongation in patients with schizophrenia

Frontiers in Psychiatry

August 1, 2022 Parkinson's Disease Psychosis

Hallucinations and delusions associated with Parkinson’s disease psychosis: safety of current treatments and future directions

Expert Opinion on Drug Safety

July 29, 2022 Parkinson's Disease Psychosis

Screening, diagnosis, and management of Parkinson’s disease psychosis: recommendations from an expert panel

Neurology and Therapy

July 23, 2022 Alzheimer's Disease Psychosis

Using telemedicine to assess and manage psychosis in neurodegenerative diseases in long-term care

Journal of the American Medical Directors Association

Load More Results

Report Adverse Event: If you have an adverse event or product complaint to report, please call contact Acadia Pharmaceuticals Inc. at 1-844-422-2342, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.